Kedrab market to grow as rabies cases and post-exposure demand rise

The Business Research Company says the Kedrab market is expanding on rising rabies cases, stronger post-exposure prophylaxis efforts and growing access to emergency care. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through 2035.

Why it matters: - Kedrab is used to help prevent rabies after a possible exposure, making it part of emergency care in a disease that is almost always fatal once symptoms appear. - Demand for rabies post-exposure treatment can rise quickly when animal bite incidents increase or vaccine access is limited. - The market outlook matters for hospitals, public health systems and manufacturers tied to rabies prevention.

What happened: - The Business Research Company published a Kedrab market report covering market size, trends and a forecast for 2026-2035. - The report says the historical market was driven by rabies fatality rates, heavy reliance on immunoglobulin treatments, limited early vaccine availability, public health emergency protocols and hospital-centered rabies management. - The report says the forecast period will be supported by more animal bite incidents, broader rabies awareness campaigns, emergency care infrastructure, better access to monoclonal antibody therapies and higher government funding for rabies prevention. - The report lists expanded rabies passive immunization, post-exposure prophylaxis, zoonotic disease control, emergency immunotherapy demand and stronger public health response frameworks as key trends. - The report says North America was the largest regional market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Kedrab is a human-derived monoclonal antibody developed for the prevention and treatment of rabies after potential exposure. - Kedrab provides passive immunity by neutralizing the rabies virus and helping prevent disease onset when given promptly. - The product is positioned as important in rabies post-exposure management, especially where vaccine access and timely treatment are limited. - The report identifies rising rabies incidence worldwide as a major driver of market growth. - Rabies remains nearly always fatal and is linked to contact with rabid animals. - The report links rising cases to inadequate vaccination of domestic animals, limited access to post-exposure prophylaxis and persistent rabies in wildlife populations, especially in underserved regions. - The report uses South Dakota as an example, citing state health data that confirmed rabies cases in animals reached about 20 in 2023, up 122% from 9 cases in 2022. - The report says that increase supports higher demand for Kedrab. - The 2026 report additions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.

Between the lines: - The market story is less about routine drug demand and more about preparedness for urgent, exposure-driven treatment needs. - Faster growth in Asia-Pacific likely reflects where rabies prevention gaps and emergency care expansion can most quickly shift demand. - The emphasis on monoclonal antibody access suggests competition may hinge on supply availability and public health procurement, not only clinical need.

What's next: - The report points to more growth if rabies awareness, emergency response systems and government prevention funding continue to expand. - Market development will likely track animal bite trends, regional vaccine access and adoption of post-exposure protocols. - The company is offering direct contact channels for buyers and analysts seeking more detail on the forecast and regional outlook. - Follow The Business Research Company on LinkedIn, Facebook and X.